GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Gross Profit

HighTide Therapeutics (HKSE:02511) Gross Profit : HK$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Gross Profit?

HighTide Therapeutics's gross profit for the six months ended in Dec. 2024 was HK$0.00 Mil. HighTide Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. HighTide Therapeutics's gross profit for the six months ended in Dec. 2024 was HK$0.00 Mil. HighTide Therapeutics's Revenue for the six months ended in Dec. 2024 was HK$0.00 Mil. Therefore, HighTide Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.

HighTide Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


HighTide Therapeutics Gross Profit Historical Data

The historical data trend for HighTide Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Gross Profit Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Gross Profit
- - - -

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross Profit Get a 7-Day Free Trial - - - - -

Competitive Comparison of HighTide Therapeutics's Gross Profit

For the Biotechnology subindustry, HighTide Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Gross Profit falls into.


;
;

HighTide Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

HighTide Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

HighTide Therapeutics's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

HighTide Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


HighTide Therapeutics  (HKSE:02511) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HighTide Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


HighTide Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Executives
Ma Lixiong 2101 Beneficial owner
Liu Liping 2101 Beneficial owner
Li Tan 2202 Interest of your spouse
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 2501 Other
Li Li 2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao 2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc. 2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p 2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited 2101 Beneficial owner
Hepalink (hong Kong) Limited 2201 Interest of corporation controlled by you
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited 2101 Beneficial owner
Lai Hoi Man 2201 Interest of corporation controlled by you

HighTide Therapeutics Headlines

No Headlines